Last updated: September 22, 2026
CSL Behring Lengnau AG is best analyzed as a strategic Swiss manufacturing and development entity within CSL Behring, not as a separately commercialized drug company. Its competitive position comes from CSL Behring’s plasma-derived and recombinant biologics portfolio, global manufacturing network, regulatory capabilities and supply-chain infrastructure. Public disclosures do not separately report Lengnau revenue, product-level margins, site-specific patents or standalone market share. The strongest defensible conclusion is that Lengnau is an operational asset supporting CSL Behring’s biologics franchise rather than an independent market participant.
What is CSL Behring Lengnau AG?
CSL Behring Lengnau AG is associated with CSL Behring’s Swiss operations in Lengnau, Canton of Bern. CSL Behring is the biopharmaceutical division of CSL Limited and focuses on plasma-derived therapies, recombinant proteins, immunoglobulins, albumin, coagulation products and specialty medicines.
The Lengnau operation should be distinguished from:
| Entity |
Role |
| CSL Limited |
Australian-listed parent company |
| CSL Behring |
Global biopharmaceutical business |
| CSL Plasma |
Plasma collection business |
| CSL Behring Lengnau AG |
Swiss legal and operational entity |
| CSL Behring manufacturing sites |
Global network supporting production and supply |
CSL’s publicly reported business segments do not generally provide a standalone financial statement for CSL Behring Lengnau AG. Product sales are reported at the CSL Behring or CSL group level rather than attributed to individual sites. This limits direct valuation of the Lengnau entity.
What is CSL Behring Lengnau AG’s market position?
CSL Behring holds a leading position in plasma-derived and specialty biologics. Its commercial strength is tied to therapies for immunodeficiency, hereditary angioedema, hemophilia, bleeding disorders, respiratory disease and other rare conditions.
Key commercial products associated with CSL Behring include:
| Product |
Active ingredient or modality |
Principal area |
| Hizentra |
Subcutaneous immune globulin |
Primary immunodeficiency |
| Privigen |
Intravenous immune globulin |
Immunodeficiency and immune-mediated disease |
| Gamunex-C |
Immune globulin |
Immunodeficiency and immune-mediated disease |
| Berinert |
C1 esterase inhibitor |
Hereditary angioedema |
| Haegarda |
C1 esterase inhibitor |
Hereditary angioedema prophylaxis |
| Idelvion |
Recombinant albumin-fused factor IX |
Hemophilia B |
| Afstyla |
Recombinant factor VIII |
Hemophilia A |
| Alprolix |
Recombinant factor IX |
Hemophilia B |
| Mononine |
Human coagulation factor IX |
Hemophilia B |
| Zemaira |
Alpha-1 proteinase inhibitor |
Alpha-1 antitrypsin deficiency |
| Albumin products |
Human albumin |
Volume replacement and related uses |
Product availability differs by country. Regulatory approvals, labels, reimbursement and manufacturing arrangements are jurisdiction-specific.
CSL Behring competes primarily with Takeda, Grifols, Octapharma, Kedrion, Biotest, Pfizer, Sanofi, Novo Nordisk, Bayer and other specialty-biologics companies.
How does CSL Behring compare with competing plasma and biologics companies?
CSL Behring’s principal advantage is vertical integration across plasma collection, fractionation, manufacturing, regulatory operations and global commercialization.
| Company |
Core strength |
Main competitive overlap |
| CSL Behring |
Plasma-derived therapies, immunoglobulins and bleeding disorders |
Takeda, Grifols, Octapharma |
| Takeda |
Immunoglobulins, rare disease and plasma-derived therapies |
CSL Behring, Grifols |
| Grifols |
Plasma collection, immunoglobulins and albumin |
CSL Behring, Takeda |
| Octapharma |
Plasma-derived and recombinant hematology products |
CSL Behring, Takeda |
| Sanofi |
Rare disease and specialty biologics |
Selected CSL products |
| Novo Nordisk |
Hemophilia, metabolic and specialty biologics |
Selected coagulation products |
| Pfizer |
Hemophilia and hospital medicines |
Selected factor products |
| Kedrion |
Plasma-derived medicines |
Immunoglobulin and albumin markets |
CSL Behring’s competitive position is strongest where supply reliability, plasma access, manufacturing scale and physician confidence influence purchasing decisions. Price competition is more pronounced in immunoglobulin and albumin markets than in highly specialized orphan products with fewer alternatives.
What strengths does CSL Behring Lengnau have?
Manufacturing and quality infrastructure
The principal strategic value of Lengnau is its role in a regulated biologics manufacturing network. Biologics facilities require validated processes, contamination control, cold-chain management, batch-release systems and long regulatory histories. Replacing such capacity can require substantial capital and several years of qualification.
Manufacturing strengths likely associated with a site such as Lengnau include:
- Swiss and European regulatory compliance
- Biologics process-control capabilities
- Quality systems for complex products
- Integration with CSL Behring’s global supply network
- Access to highly trained technical personnel
- Potential flexibility for process development or product transfer
- Support for products requiring strict temperature and handling controls
The exact product-to-site allocation is not fully disclosed in public corporate materials. A site’s strategic importance therefore cannot be inferred solely from the presence of CSL Behring’s legal entity in Lengnau.
Supply-chain integration
CSL Behring controls or coordinates important upstream and downstream activities. The broader network includes plasma collection, testing, fractionation, purification, filling, packaging and distribution.
This structure can reduce exposure to external suppliers, but it does not eliminate risk. Plasma availability, donor collection, labor, regulatory inspections, energy costs, single-site dependencies and transportation remain material variables.
Regulatory credibility
CSL Behring operates products regulated by the U.S. Food and Drug Administration, European Medicines Agency, Swissmedic and other national authorities. Its experience with biologics license applications, supplemental approvals, manufacturing changes and post-market obligations creates a barrier for smaller competitors.
Regulatory credibility is particularly valuable for plasma-derived products because quality depends on donor screening, viral safety, purification, validation and continuous process monitoring.
What patents protect CSL Behring products?
Patent protection for CSL Behring products generally resides at the product, formulation, manufacturing-process and method-of-use levels. The patents are usually owned by CSL Behring, CSL Limited affiliates or predecessor companies. Public information does not establish that CSL Behring Lengnau AG owns the full patent estate for products manufactured at the Lengnau site.
Relevant patent categories include:
| Patent category |
Commercial purpose |
| Composition patents |
Protect engineered proteins or molecular constructs |
| Formulation patents |
Protect concentration, stabilizers, buffers and excipients |
| Manufacturing patents |
Protect purification, fractionation, viral inactivation or recombinant production |
| Delivery patents |
Protect subcutaneous, intravenous or other administration systems |
| Method-of-use patents |
Protect treatment, prophylaxis or dosing regimens |
| Device patents |
Protect injectors, containers and administration components |
| Process-control patents |
Protect manufacturing and analytical methods |
For biologics, regulatory exclusivity, manufacturing know-how and trade secrets can be as important as issued patents. Patent expiry does not automatically create immediate market entry because a biosimilar applicant must establish analytical similarity, manufacturing comparability and clinical or immunogenicity evidence where required.
What is the Orange Book status of CSL Behring products?
The FDA Orange Book primarily covers approved small-molecule drugs and certain drug products. It is not the principal source for biologic reference-product patent information.
For biological products, the relevant U.S. sources are generally:
- FDA Purple Book listings
- Biologics License Application records
- FDA patent-certification information for applicable products
- USPTO records
- Federal district court and Federal Circuit litigation records
- FDA approval letters and product labeling
Many CSL Behring products are biologics or plasma-derived products. Their U.S. exclusivity and biosimilar issues should therefore be analyzed through the Public Health Service Act framework, the Purple Book and product-specific FDA records rather than by assuming an Orange Book listing.
When do CSL Behring products lose exclusivity?
There is no single CSL Behring exclusivity date. Each product may have separate patent, regulatory exclusivity, orphan-drug and pediatric-exclusivity periods.
Regulatory exclusivity
For biologics approved under the Public Health Service Act, the reference product generally receives 12 years of reference-product exclusivity before FDA approval of a biosimilar referencing that product, subject to statutory limitations. Orphan-drug exclusivity can provide seven years for qualifying indications. Pediatric exclusivity can add six months to certain existing protections.
These periods do not necessarily align with patent expiration. A product may face biosimilar competition after regulatory exclusivity ends while patent disputes continue.
Patent expiry
Patent expiry depends on:
- Priority date
- Patent term adjustment
- Patent term extension
- Terminal disclaimers
- Continuation practice
- Jurisdiction
- Claim scope
- Litigation outcomes
- Patent settlements
A site-level company search cannot substitute for a product-level patent review. Patent expiration dates must be verified against individual patent records and applicable national registers.
Are CSL Behring products exposed to Paragraph IV challenges?
Paragraph IV litigation applies primarily to abbreviated new drug applications for small-molecule drugs under the Hatch-Waxman Act. Biologics generally proceed through the biosimilar pathway under the Biologics Price Competition and Innovation Act.
For CSL Behring’s biologic portfolio, the more relevant questions are:
- Whether a biosimilar or interchangeable product has been filed.
- Whether the reference product is listed in the FDA Purple Book.
- Whether patent-information exchanges occurred under the BPCIA.
- Whether the biosimilar sponsor filed a declaratory action or faced patent litigation.
- Whether a settlement establishes a future launch date.
- Whether manufacturing and device patents remain enforceable.
Products that are small-molecule drugs or combination products may present different litigation pathways. The applicable procedure must be determined product by product.
What biosimilar risks affect CSL Behring?
Biosimilar risk is most relevant to large, established biologics with significant revenue, broad reimbursement and technically feasible development pathways. The risk profile differs across CSL Behring’s portfolio.
| Product class |
Biosimilar risk |
Main reason |
| Intravenous immune globulin |
Moderate |
Complex source material and manufacturing requirements limit entrants, but demand attracts competition |
| Subcutaneous immune globulin |
Moderate |
Device, formulation and administration requirements add barriers |
| Recombinant factor VIII and IX |
Moderate to high |
Established recombinant technology and multiple competitors |
| C1 esterase inhibitor |
Low to moderate |
Smaller market and product-specific manufacturing complexity |
| Albumin |
Moderate |
Established product with supply and price competition |
| Alpha-1 proteinase inhibitor |
Low to moderate |
Limited market size and specialized manufacturing |
Immunoglobulin products have a distinctive risk profile. Demand growth can support pricing, but supply shortages and capacity constraints may delay or limit competitive entry. In coagulation products, non-patent competition also comes from alternative mechanisms, extended half-life products and gene therapies.
What patent litigation affects CSL Behring?
Patent litigation should be separated into three categories:
Product litigation
This involves patents covering the active biologic, formulation, dosing method or delivery system. Public litigation activity can change rapidly and requires a live review of court dockets.
Biosimilar litigation
Biosimilar disputes may involve the BPCIA patent dance, declaratory judgments, infringement actions, preliminary injunctions and negotiated launch dates.
Manufacturing litigation
Manufacturing patents may be particularly important for plasma-derived products because competitors must demonstrate comparable purification, viral inactivation and quality performance. Trade-secret disputes can also affect manufacturing know-how, although those rights are not visible in patent registers.
No comprehensive public record attributes all CSL Behring litigation to CSL Behring Lengnau AG. The proper defendant may instead be CSL Behring LLC, CSL Behring GmbH, CSL Limited or another affiliate.
What licensing deals support CSL Behring’s position?
CSL Behring’s portfolio has been shaped by acquisitions, product rights, collaborations and internal development. Notable strategic transactions involving the wider CSL group include the acquisition of Vifor Pharma, which expanded CSL’s specialty pharmaceutical and nephrology presence.
Licensing and acquisition analysis should distinguish:
- Asset ownership
- Marketing rights
- Manufacturing rights
- Territory-specific rights
- Patent ownership
- Royalty obligations
- Supply agreements
- Co-development arrangements
A manufacturing entity such as CSL Behring Lengnau AG may produce a product without owning its global patents or commercial rights. Site ownership, patent ownership and product ownership are separate legal questions.
How strong is the CSL Behring patent estate?
The broader CSL Behring patent estate is strategically strong where it combines multiple protection layers:
- Core molecule or engineered-protein protection.
- Formulation and stability claims.
- Manufacturing-process claims.
- Delivery-device protection.
- Method-of-use claims.
- Regulatory exclusivity.
- Trade secrets and validated manufacturing know-how.
Patent strength is weaker when protection relies mainly on late-expiring method-of-use claims, narrow formulation claims or patents that can be designed around. It is stronger when a competitor would need to replicate a validated process, obtain difficult-to-source biological material and overcome multiple independent claim sets.
A reliable patent-strength score requires a product-by-product claim chart. A corporate-level patent count would not adequately measure blocking power.
What generic and biosimilar launch scenarios exist?
Scenario 1: No near-term competitor
This occurs when regulatory exclusivity, patents, manufacturing complexity or limited commercial opportunity delay entry.
Scenario 2: Negotiated launch
A biosimilar sponsor resolves litigation through a settlement allowing launch before the latest asserted patent expiration. Such agreements can preserve some exclusivity while defining market-entry timing.
Scenario 3: Early launch after successful challenge
A challenger may invalidate or avoid key patents, creating accelerated competition. Price erosion depends on the number of entrants and payer contracting.
Scenario 4: Non-biosimilar substitution
Revenue can decline even without a direct biosimilar if physicians and payers shift to alternative mechanisms, longer-acting products, gene therapies or competing plasma-derived products.
Scenario 5: Capacity-constrained competition
A biosimilar may obtain approval but remain commercially limited by manufacturing scale, launch supply, cold-chain capability or reimbursement access.
What is the revenue exposure of CSL Behring Lengnau AG?
Revenue exposure cannot be assigned reliably to CSL Behring Lengnau AG from public group-level reporting. CSL reports financial performance for business divisions and product categories, not necessarily for individual manufacturing subsidiaries.
The relevant exposure indicators are:
- Share of CSL Behring sales from products manufactured at or supported by Lengnau
- Number of qualified alternative sites
- Product transfer feasibility
- Site inspection history
- Capacity utilization
- Single-source dependencies
- Product contribution margins
- Expected biosimilar entry dates
- Reimbursement and pricing pressure
A high-value product manufactured at one site would create operational concentration risk even if the site’s legal entity has little standalone revenue.
What regulatory status does CSL Behring Lengnau have?
The entity operates within a Swiss and international regulated manufacturing framework. Relevant oversight may include:
- Swissmedic
- European national competent authorities
- European Medicines Agency procedures
- FDA inspections and biologics requirements
- Health Canada
- Australian Therapeutic Goods Administration
- Other national regulators
The regulatory status of the site should be assessed through facility registrations, inspection outcomes, warning letters, Form 483 records where available, import alerts, product approvals and manufacturing authorizations. Corporate affiliation alone does not establish approval to manufacture every CSL Behring product.
What geographic coverage does CSL Behring have?
CSL Behring sells products across North America, Europe, Asia-Pacific, Latin America and other international markets. Geographic protection depends on local patents, regulatory approvals, reimbursement decisions, data exclusivity and manufacturing authorization.
The same product can have different competitive timing in the United States, European Union, Switzerland, Japan and emerging markets. U.S. biosimilar entry may occur years before or after competition in other jurisdictions.
Key Takeaways
- CSL Behring Lengnau AG is best viewed as a Swiss operational entity within the CSL Behring network.
- Its market position derives from CSL Behring’s global biologics, plasma and specialty-medicine franchise.
- Public disclosures do not separately report Lengnau revenue, product share, site-specific patent ownership or standalone market share.
- The strongest competitive barriers are plasma access, manufacturing scale, quality systems, regulatory experience and supply reliability.
- Orange Book analysis is generally insufficient for CSL Behring’s biologic products; Purple Book and BPCIA analysis are more relevant.
- Biosimilar risk varies by product class and depends on patent layering, manufacturing complexity, reimbursement and competitor capacity.
- Patent strength must be measured at the product and claim level, not by the existence of a CSL Behring manufacturing entity.
- Manufacturing know-how and validated processes may remain important after core patents expire.
- Revenue concentration and site dependency are the key commercial risks that cannot be quantified from public entity-level reporting.
- Competitive analysis should focus on CSL Behring globally, with Lengnau assessed as a manufacturing, regulatory and supply-chain asset.
FAQs About CSL Behring Lengnau AG
Is CSL Behring Lengnau AG a separate pharmaceutical company?
No. It is a Swiss legal and operational entity associated with CSL Behring. Commercial strategy and product economics are generally reported at the CSL Behring or CSL group level.
Does CSL Behring Lengnau AG own CSL Behring patents?
Not necessarily. Patent ownership may reside with CSL Behring, CSL Limited affiliates or other entities. Manufacturing location and patent ownership are separate issues.
Are CSL Behring products listed in the FDA Orange Book?
Many CSL Behring products are biologics or plasma-derived products, for which the FDA Purple Book and biologic regulatory records are more relevant than the Orange Book.
Which companies compete most directly with CSL Behring?
Takeda, Grifols, Octapharma, Kedrion and Biotest are major competitors in plasma-derived products. Sanofi, Novo Nordisk, Pfizer and other companies compete in selected specialty and coagulation markets.
What is the main strategic risk to CSL Behring Lengnau?
The main risks are manufacturing concentration, regulatory findings, supply disruption, product transfer difficulty, biosimilar competition and loss of demand to alternative therapies.
References
-
CSL Limited. (2024). Annual report 2024. CSL Limited.
-
CSL Behring. (2024). Products and therapies. CSL Behring.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. U.S. Department of Health and Human Services.
-
European Medicines Agency. (2024). Biosimilar medicines: Overview. European Union.
-
Swissmedic. (2024). Medicinal products and manufacturing authorisations. Swiss Agency for Therapeutic Products.
-
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension. U.S. Department of Commerce.
